Connor Clark & Lunn Investment Management Ltd. grew its position in Eton Pharmaceuticals, Inc. (NASDAQ:ETON – Free Report) by 86.6% in the 3rd quarter, HoldingsChannel.com reports. The institutional ...

Equities research analysts at HC Wainwright dropped their FY2024 earnings per share estimates for shares of Eton ...

Summary The Chart of the Day belongs to the pharmaceutical company Eton Pharmaceuticals (ETON) . I found the stock by using ...

Amglidia® has been approved by the European Medicines Agency (EMA) and is commercially available in EuropeStrong strategic fit with Eton’s ...

PUREPWR Nutrition announces the launch of HexaBlend Creatine Gummies, a breakthrough in sports supplementation, combining six ...

It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the ...

Reported total revenue of $10.3 million and GAAP Net Income of $0.6 million, or $0.02 per diluted shareEntered into an asset purchase agreement to acquire Increlex® (mecasermin injection)Q3 2024 produ ...

The commercial availability of Betaine Anhydrous, Nitisinone, and PKU GOLIKE® has helped increase the frequency of the Company’s interactions with potential Carglumic Acid prescribers.

The Company currently has five commercial rare disease products: ALKINDI SPRINKLE®, PKU GOLIKE®, Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has three additional product ...